In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on HCW Biologics (HCWB – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $2.23.
Okunewitch covers the Healthcare sector, focusing on stocks such as Kiora Pharmaceuticals, Citius Pharmaceuticals, and HCW Biologics. According to TipRanks, Okunewitch has an average return of -19.6% and a 29.41% success rate on recommended stocks.
Currently, the analyst consensus on HCW Biologics is a Moderate Buy with an average price target of $4.00.
See today’s best-performing stocks on TipRanks >>
HCWB market cap is currently $79.83M and has a P/E ratio of -6.22.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HCWB in relation to earlier this year. Most recently, in June 2022, Jiao Jin-an, the VP of Development of HCWB bought 14,570.00 shares for a total of $2,159.77.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HCW Biologics Inc is a preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases. It is developing HCW9218 as an injectable immunotherapeutic for patients with solid tumors.
Read More on HCWB:
